Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.72 |
| ▸ | HRH1 | P35367 | 3/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4915137 | 0.86 | HRH3 (0.72) | HRH3HRH1OPRM1OPRD1OPRK1 | |
| SCHEMBL29496216 | 0.83 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL3091166 | 0.83 | HRH3 (0.96) | HRH3HRH1 | |
| SCHEMBL167107 | 0.83 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL29665214 | 0.83 | HRH3 (1.00) | HRH3HRH1 | |
| SCHEMBL167108 | 0.80 | HRH3 (0.68) | HRH3HRH1OPRM1OPRD1OPRK1 | |
| SCHEMBL3087351 | 0.80 | HRH3 (0.80) | HRH3HRH1 | |
| SCHEMBL3077258 | 0.79 | HRH3 (0.67) | HRH3HRH1CYP2D6 | |
| SCHEMBL3089265 | 0.79 | HRH3 (0.66) | HRH3HRH1OPRM1OPRD1OPRK1 | |
| SCHEMBL4399987 | 0.77 | HRH3 (0.72) | HRH3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | claimed |
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| EP-1735299-A1 | TERTRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005097778-A1 | TETRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | HRH3, HRH4, HRH1 | HRH3 1/4885HRH1 3/4885CYP2D6 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.